Overall survival of myelodysplastic syndrome with excess blasts (MDS-EB) and acute myeloid leukemia (AML) at diagnosis subclassified by wild-type TP53 and mutated TP53 cases. Patient survival in this cohort is stratified by the presence or absence of TP53 mutation, not classification as MDS-EB versus AML (modified from Figure 2B, Grob et al. Blood. 2022).